Fresh Recalls

FDAClass I · Drug · Recall D-0732-2026 · Recalled July 29, 2026

Cetirizine Hydrochloride Tablets USP 5 mg recall — JB Chemicals and Pharmaceuticals Ltd

Agency report date: July 29, 2026.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named
Cetirizine Hydrochloride Tablets USP 5 mg
Company / brand
JB Chemicals and Pharmaceuticals
Lot / serial / date codes
Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT
Distribution
Nationwide in the USA
Agency product description and boundaries

Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

2. Agency hazard and consumer action

FDA reports: Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

No consumer remedy instructions are supplied in this record. Check the official notice and listed company contact for the agency’s current instructions.

Class I: most serious — reasonable probability of serious health consequences or death.

Affected product: Cetirizine Hydrochloride Tablets USP 5 mg

3. Open the official notice or contact

Official recall ID
D-0732-2026
Brand
JB Chemicals and Pharmaceuticals
Classification
Class I
Units affected
34,020 100-count bottles.
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Affected products

Companies & origin

Recalling firm location
Mumbai, N/A, India
Firm address
Neelam Centre A Wing A B Wing, 4th Floor; Hind Cycle Road, N/A

Identifying details (verbatim from the notice)

Product codes / lots
Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT
Distribution
Nationwide in the USA
Firm notified the public via
Letter
FDA event ID
99321
Recall initiated
June 24, 2026
FDA classified
August 3, 2026
FDA report date
July 29, 2026
Verify with the official sources:

Found something wrong or missing? Report a data error.

Source: U.S. Food & Drug Administration. Agency excerpts come from the public data feed and may omit tables or later changes; the linked government source is authoritative. Source last checked September 7, 2026 at 6:00 AM UTC. Record retrieved September 7, 2026 at 6:00 AM UTC.

Report a data error on this page